AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection

At a time, the AMP-511 EAP will enrol up to 100 active Chronic Fatigue Syndrome trial subjects. Credit: Yuri Samoilov/yuri.samoilov.online.